BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference

LYNBROOK, N.Y., Sept. 4, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S and XIAPEX® in the EU, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the Stifel Nicolaus 2013 Healthcare Conference at 9:10 a.m. EDT on Wednesday, September 11, 2013 in Boston, MA.

The live webcast of this presentation can be accessed under "Events & Presentation" in the Investors section of the Company's website at www.biospecifics.com or at the link http://www.veracast.com/webcasts/stifel/healthcare2013/07103451774.cfm.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum (CCH)) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) and marketed in Europe and approved in Canada. Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU trade name for CCH) for the treatment of Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan and Actelion Pharmaceuticals Ltd. has development and commercialization rights for XIAFLEX for these two indications in Canada, Mexico, Brazil and Australia. CCH is in clinical development for the treatment of several additional promising indications. The PDUFA date for XIAFLEX for Peyronie's disease is December 6, 2013. Auxilium is also testing CCH for frozen shoulder syndrome and cellulite. Auxilium expects to initiate a Phase II trial of CCH for cellulite in the third quarter of this year and next stage trials of CCH for frozen shoulder syndrome in the fourth quarter of 2013. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase II trials. BioSpecifics expects top-line data from these trials in the second half of the year. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.



RELATED LINKS
http://www.biospecifics.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.